- Home
- PSNYW vs PRTA Comparison
PSNYW vs PRTA Comparison
Compare PSNYW & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- PRTA
- Stock Information
- Founded
- PSNYW 2017
- PRTA 2012
- Country
- PSNYW Sweden
- PRTA Ireland
- Employees
- PSNYW 2547
- PRTA N/A
- Industry
- PSNYW Auto Manufacturing
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- PSNYW Consumer Discretionary
- PRTA Health Care
- Exchange
- PSNYW Nasdaq
- PRTA Nasdaq
- Market Cap
- PSNYW 625.2M
- PRTA 472.1M
- IPO Year
- PSNYW N/A
- PRTA N/A
- Fundamental
- Price
- PSNYW $0.30
- PRTA $8.20
- Analyst Decision
- PSNYW
- PRTA Buy
- Analyst Count
- PSNYW 0
- PRTA 10
- Target Price
- PSNYW N/A
- PRTA $14.86
- AVG Volume (30 Days)
- PSNYW 43.4K
- PRTA 1.2M
- Earning Date
- PSNYW 03-06-2025
- PRTA 08-04-2025
- Dividend Yield
- PSNYW N/A
- PRTA N/A
- EPS Growth
- PSNYW N/A
- PRTA N/A
- EPS
- PSNYW N/A
- PRTA N/A
- Revenue
- PSNYW $2,034,261,000.00
- PRTA $10,341,000.00
- Revenue This Year
- PSNYW N/A
- PRTA N/A
- Revenue Next Year
- PSNYW $79.49
- PRTA $389.77
- P/E Ratio
- PSNYW N/A
- PRTA N/A
- Revenue Growth
- PSNYW N/A
- PRTA N/A
- 52 Week Low
- PSNYW $0.09
- PRTA $4.32
- 52 Week High
- PSNYW $0.61
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- PSNYW 56.04
- PRTA 58.73
- Support Level
- PSNYW $0.16
- PRTA $8.05
- Resistance Level
- PSNYW $0.80
- PRTA $8.73
- Average True Range (ATR)
- PSNYW 0.06
- PRTA 0.38
- MACD
- PSNYW 0.02
- PRTA -0.05
- Stochastic Oscillator
- PSNYW 15.62
- PRTA 47.62
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.